Raaj Medisafe

how big is Raaj Medisafe?

As of Jun 06, Raaj Medisafe India Ltd has a market capitalization of 108.00 Cr, categorizing it as a Micro Cap company, with total assets of 41.51 Cr and shareholder's funds of 10.84 Cr as of Mar'24.

Market Cap: As of Jun 06, Raaj Medisafe India Ltd has a market capitalization of 108.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest two quarters, which includes data from Mar'16 and Mar'15, is 1.05 Cr. The sum of Net Profit for the same periods is 0.00 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 10.84 Cr, while the Total Assets amount to 41.51 Cr.

What does Raaj Medisafe do?

Raaj Medisafe India Ltd manufactures medical disposable devices and operates in the micro-cap packaging industry. As of March 2025, it reported net sales of ₹24 Cr and a net profit of ₹3 Cr, with a market cap of ₹108 Cr.

Overview:<BR>Raaj Medisafe India Ltd is engaged in the manufacturing of medical disposable devices and operates within the micro-cap segment of the packaging industry.<BR><BR>History:<BR>The company was incorporated in September 1985 under the name Manoj Surgical Industries Limited, which was later changed to Raaj Medisafe India Limited in July 2008. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 24 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 3 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: Rs 108 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 18.00<BR>- Industry P/E: 22<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 1.24<BR>- Return on Equity: 27.28%<BR>- Price to Book: 4.82<BR><BR>Contact Details:<BR>Address: 106 Sector III, Industrial Area Pithampur Dhar Madhya Pradesh : 454774<BR>Tel: 91-7292-403192<BR>Email: info@medisafeindia.com<BR>Website: http://www.raajmedisafeindia.com

Has Raaj Medisafe declared dividend?

No Dividend History Available

Who are the peers of the Raaj Medisafe?

Raaj Medisafe's peers include EPL Ltd, AGI Greenpac, Uflex, Polyplex Corpn, TCPL Packaging, Shetron, AMD Industries, Guj. Containers, Orient Press, and Guj. Craft Inds. Raaj Medisafe shows excellent growth and average management risk, with a 1-year return of 22.24%, lower than Polyplex Corpn's 66.57% but higher than AMD Industries' -19.81%.

Peers: The peers of Raaj Medisafe are EPL Ltd, AGI Greenpac, Uflex, Polyplex Corpn, TCPL Packaging, Shetron, AMD Industries, Guj. Containers, Orient Press, and Guj. Craft Inds.<BR><BR>Quality Snapshot: Excellent management risk is observed at EPL Ltd and Guj. Containers, while Average management risk is found at AGI Greenpac, Uflex, Polyplex Corpn, TCPL Packaging, Raaj Medisafe, Shetron, and Guj. Craft Inds, and the rest. Below Average management risk is noted at AMD Industries and Orient Press. Growth is Excellent at Raaj Medisafe, Average at AGI Greenpac, TCPL Packaging, and the rest, and Below Average at EPL Ltd, Uflex, Polyplex Corpn, Shetron, AMD Industries, Guj. Containers, and Orient Press. Capital Structure is Excellent at Polyplex Corpn, Good at EPL Ltd and Guj. Containers, Average at AGI Greenpac, TCPL Packaging, and the rest, and Below Average at Uflex, Raaj Medisafe, Shetron, AMD Industries, and Orient Press.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Polyplex Corpn at 66.57%, while the lowest is AMD Industries at -19.81%. Raaj Medisafe's 1-year return of 22.24% is higher than AMD Industries but lower than Polyplex Corpn. Additionally, the six-month return is negative for Shetron, AMD Industries, and Orient Press.

Is Raaj Medisafe overvalued or undervalued?

As of May 27, 2025, Raaj Medisafe's valuation has improved to very attractive, with strong growth potential indicated by a PE ratio of 17.03, an EV to EBITDA of 15.33, and a PEG ratio of 0.33, making it undervalued compared to peers like Poly Medicure and Blue Jet Health, despite recent underperformance against the Sensex.

As of 27 May 2025, the valuation grade for Raaj Medisafe has moved from attractive to very attractive, indicating a positive shift in its investment appeal. The company is currently undervalued, with a PE ratio of 17.03, an EV to EBITDA of 15.33, and a PEG ratio of 0.33, suggesting strong growth potential relative to its price. <BR><BR>In comparison to peers, Raaj Medisafe's valuation metrics stand out, particularly when contrasted with Poly Medicure, which has a PE ratio of 66.7, and Blue Jet Health at 51.29, both categorized as very expensive. The company's return on equity (ROE) is notably high at 27.28%, further reinforcing its attractive valuation. Despite recent underperformance against the Sensex, with a year-to-date return of -8.43% compared to the Sensex's 5.59%, the long-term performance over three and five years shows significant outperformance, suggesting that the current price presents a compelling buying opportunity.

What is the technical trend for Raaj Medisafe?

As of June 3, 2025, Raaj Medisafe's technical trend is mildly bearish, influenced by daily moving averages and a monthly MACD, despite some mixed signals from the weekly MACD and Bollinger Bands.

As of 3 June 2025, the technical trend for Raaj Medisafe has changed from sideways to mildly bearish. The weekly MACD is bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are mildly bearish, reinforcing the current trend. The Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames, which contrasts with the overall bearish sentiment. The KST is bullish weekly but mildly bearish monthly, while Dow Theory indicates a mildly bearish trend on the weekly chart. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly MACD.

Who are in the management team of Raaj Medisafe?

As of March 2022, the management team of Raaj Medisafe includes Arpit Bangur (Chairman), Navin Jhawar (Managing Director), and four Independent Directors: Rajesh Kumar Gupta, Vijendra Kumar Sood, and Krishna Jajoo, along with Sachin Sarda (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2022, the management team of Raaj Medisafe includes the following individuals:<BR><BR>1. Arpit Bangur - Chairman (Non-Executive)<BR>2. Rajesh Kumar Gupta - Independent Director<BR>3. Vijendra Kumar Sood - Independent Director<BR>4. Krishna Jajoo - Independent Director<BR>5. Sachin Sarda - Company Secretary & Compliance Officer<BR>6. Navin Jhawar - Managing Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the top shareholders of the Raaj Medisafe?

The top shareholders of Raaj Medisafe include Sushen Remedies Private Limited with 19.14%, individual investors with 23.05%, and Ramesh Chand Maheshvari as the highest public shareholder at 2.42%. There are no mutual funds or foreign institutional investors currently holding shares in the company.

The top shareholders of Raaj Medisafe include the promoters, with Sushen Remedies Private Limited holding the largest stake at 19.14%. Additionally, individual investors collectively own 23.05% of the company. The highest public shareholder is Ramesh Chand Maheshvari, who holds 2.42%. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

How has been the historical performance of Raaj Medisafe?

Raaj Medisafe has shown significant growth from March 2019 to March 2025, with net sales increasing from 4.80 Cr to 62.42 Cr and a turnaround from losses to profits in operating profit, profit before tax, and profit after tax. Total assets rose from 13.59 Cr to 68.06 Cr, indicating strong financial recovery and growth.

Answer:<BR>The historical performance of Raaj Medisafe shows significant growth in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Raaj Medisafe's net sales have increased from 4.80 Cr in March 2019 to 62.42 Cr in March 2025, reflecting a robust growth trajectory. Total operating income followed a similar trend, rising from 4.80 Cr in March 2019 to 62.42 Cr in March 2025. The company's operating profit (PBDIT) has also improved, moving from a loss of 0.78 Cr in March 2019 to a profit of 8.83 Cr in March 2025. Profit before tax has shown a positive trend, increasing from a loss of 1.59 Cr in March 2019 to a profit of 5.25 Cr in March 2025, while profit after tax reached 6.13 Cr in March 2025, up from a loss of 1.36 Cr in March 2020. The company's total assets have expanded significantly from 13.59 Cr in March 2020 to 68.06 Cr in March 2025, with total liabilities also increasing from 13.59 Cr to 34.51 Cr during the same period. Cash flow from operating activities remained stable, while cash flow from investing activities showed a negative trend, indicating ongoing investments in growth. Overall, Raaj Medisafe has demonstrated a strong recovery and growth in its financial performance over the years.

When is the next results date for Raaj Medisafe India Ltd?

The next results date for Raaj Medisafe India Ltd is 11 February 2026.

The next results date for Raaj Medisafe India Ltd is scheduled for 11 February 2026.

Are Raaj Medisafe India Ltd latest results good or bad?

Raaj Medisafe India Ltd's latest results for FY25 are strong, with a 44.2% revenue increase to ₹62.00 crores and a net profit doubling to ₹6.00 crores. However, concerns about a slight decrease in operating margin and a high debt-to-equity ratio suggest potential risks for investors.

Raaj Medisafe India Ltd's latest results for FY25 indicate a strong performance overall, showcasing significant growth and profitability. The company reported an annual revenue of ₹62.00 crores, which is a remarkable increase of 44.2% year-on-year. Additionally, net profit doubled to ₹6.00 crores, reflecting a 100% increase compared to the previous fiscal year. This growth is complemented by an impressive average return on equity (ROE) of 82.82%, highlighting the company's efficiency in generating returns for shareholders.<BR><BR>Despite these positive indicators, there are some concerns to consider. The operating margin has slightly decreased to 12.9% from 14.0% in FY24, indicating some pressure on operational efficiency as the company scales. Moreover, the company operates with a high debt-to-equity ratio of 1.77, which raises questions about its leverage and ability to manage debt, especially as interest costs have also increased.<BR><BR>In summary, while Raaj Medisafe India Ltd has demonstrated exceptional growth and profitability, the high leverage and slight margin pressure warrant careful monitoring. Overall, the results can be viewed as good, but potential investors should be aware of the associated risks.

Should I buy, sell or hold Raaj Medisafe India Ltd?

Which are the latest news on Raaj Medisafe?

Why is Raaj Medisafe India Ltd falling/rising?

As of 13-Feb, Raaj Medisafe India Ltd's stock price is at Rs 89.53, down 5.0%, and has underperformed its sector. Despite a significant increase in investor participation, the stock continues to show a downward trend, remaining below its short-term moving averages.

As of 13-Feb, Raaj Medisafe India Ltd's stock price is falling, currently at Rs 89.53, which represents a decrease of Rs 4.71 or 5.0%. This decline is reflected in the stock's performance today, where it underperformed its sector by 2.56%. Additionally, the stock has shown erratic trading patterns, having not traded on 2 out of the last 20 days. The stock reached an intraday low of Rs 89.53, indicating a significant drop.<BR><BR>In the context of broader market trends, the Medical Equipment/Supplies/Accessories sector has also experienced a decline of 2.58%. Over the past week, Raaj Medisafe's stock has decreased by 1.62%, which is worse than the Sensex's decline of 1.14%. Furthermore, the stock has underperformed over the past month, with a drop of 4.76% compared to the Sensex's 1.20% decline.<BR><BR>Despite these negative trends, there has been a notable increase in investor participation, with delivery volume rising by 185.71% against the 5-day average. However, this increase in trading volume has not translated into a positive price movement, as the stock remains lower than its 5-day and 20-day moving averages, although it is higher than its 50-day, 100-day, and 200-day moving averages. Overall, the combination of sector performance, stock-specific trading patterns, and current price movements indicates that Raaj Medisafe India Ltd is experiencing a downward trend.